PT  - JOURNAL ARTICLE
AU  - Thomas Sherman
AU  - Vasant Raman
TI  - Incomplete scleral penetration of dexamethasone (Ozurdex) intravitreal implant
AID  - 10.1136/bcr-2018-227055
DP  - 2018 Nov 01
TA  - BMJ Case Reports
PG  - e227055
VI  - 11
IP  - 1
4099  - http://casereports.bmj.com/content/11/1/e227055.short
4100  - http://casereports.bmj.com/content/11/1/e227055.full
SO  - BMJ Case Reports2018 Nov 01; 11
AB  - Ozurdex (Allergan, Irvine, California, USA) is a biodegradable sustained release intravitreal implant containing 0.7 mg dexamethasone in a solid polymer drug delivery system. In the UK, it is approved for use in patients with macular oedema secondary to retinal vein occlusion, diabetic maculopathy and non-infectious uveitis. Although the implant is meant to be injected into the vitreous cavity, it can be inadvertently injected into the crystalline lens. This can also migrate into the anterior chamber, under altered anatomical conditions of the anterior segment. We report a case of incompletely penetrated dexamethasone implant, in a patient undergoing treatment for macular oedema secondary to retinal vein occlusion. The partially penetrated implant was managed conservatively with a good outcome.